Navigation Links
London Genetics Conference Proceedings Published in Drug Discovery Today
Date:5/12/2010

LONDON, May 12, 2010 /PRNewswire/ -- London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, is pleased to announce that the importance of this approach is being highlighted with the publication of its inaugural conference [1] proceedings in the May 2010 issue of Drug Discovery Today. The conference, 'Harnessing Genetic Knowledge To Improve Clinical Development and Patient Care'[2], brought together pharma and biotech companies, academia and regulatory bodies to discuss the value that pharmacogenetics can bring to drug development.

Recognising that pharmacogenetics is a key part of the mission to get the right drug to the right patient at the right dose, delegates discussed how to integrate it more fully into drug development. Issues debated ranged from the role of pharmacogenetics in cost-effectiveness studies, possible changes in the way clinical trials are performed, and the need for sophisticated bioinformatics to capture and analyse data. One of the conclusions reached was that early collaboration between academia, industry, the regulatory authorities, and those that foot the healthcare bill was pivotal for capturing the maximum potential from pharmacogenetics.

Dominique Kleyn, CEO of London Genetics, said 'Drug Discovery Today is recognised as being at the cutting edge of new developments underlying R&D in the pharma and biotech industry. Publication of our article provides a strong validation of the potential of pharmacogenetics, and the importance of the issues raised at London Genetics' inaugural conference. We look forward to discussing progress in the field at our second pharmacogenetics conference, to be held in November 2010 in Windsor, UK.'

To access the Drug Discovery Today article, please go to http://bit.ly/bVrRpv, where it is available as a download.

[1] Editorial: Pharmacogenetics - pivotal to the future of the biopharmaceutical industry. Drug Discovery Today pp 325-327, Volume 15, Numbers 9/10, May 2010.

[2] 1st Annual London Genetics Pharmacogenetics Conference 'Harnessing Genetic Knowledge to Improve Clinical Development and Patient Care', 23rd -24th September 2009, Tylney Hall, Hampshire, UK.

Notes to Editors:

About London Genetics

London Genetics Limited, a not-for-profit company, is an expert in the use of pharmacogenetics in clinical drug discovery and development. Established in 2007 with funding from the London Development Agency, its seven founding partners are leading London academic and medical institutions with clinical and genetic expertise and significant patient resources. The company provides pharmaceutical and biotechnology companies with access to this expertise and resource, as well as providing strategic advice on the application of pharmacogenetics for successful drug development. LGL has broad therapeutic expertise with a focus on cardiovascular disease and drug side-effects of a cardiovascular nature. Recent agreements developed by London Genetics include a collaboration between the International Serious Adverse Events Consortium, St George's University of London and the Drug Safety Research Unit at Southampton, UK. The parties are working on genetic markers for drug-induced cardiac arrhythmia. LGL is based in central London and has ISO 9001 accreditation. For further information, please go to http://www.londongenetics.com

About pharmacogenetics

Genetic differences between individuals mean that drug response rates are often variable across a population, and this has significant implications for healthcare cost effectiveness. Pharmocogenetics, the study of the clinical consequences of genetic differences in the way people metabolise and respond to drugs, is expected to generate better understanding of how drugs work in the body, and therefore give insight into how to develop more efficacious and safer drugs. It also has implications for product life cycle management and the revitalisation of drugs which previously failed in clinical trials. With drug development costs rising and R&D productivity falling, plus increased regulator focus on safety and cost-effectiveness, pharmacogenetics is expected to become increasingly important in drug development. The FDA and the EMA have recognised this in their Critical Path Initiative and Road Map respectively.

    For further information please contact:
    London Genetics Ltd
    Dominique Kleyn, CEO +44(0)207-594-1838
    Emma Palmer Foster, Strategic Communications Consultant
    +44(0)7880-787185
    communications@londongenetics.com


'/>"/>
SOURCE London Genetics Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Awards Made by London Genetics Proof-of-Concept Fund
2. Expanded London Genetics Web Site Emphasises Importance of Pharmacogenetics in Drug Development
3. Hologic to Present at NASDAQ OMX 23rd Investor Program in London
4. London Genetics Focuses on Partnering Following Successful Pharmacogenetics Conference
5. PRA International: Participating Sponsor for Exploratory Clinical Development World in London
6. Interleukin Genetics, Inc. Announces Conference Call to Discuss First Quarter 2010 Results
7. NYSE Amex Provides Interleukin Genetics, Inc. Extension To Meet Continued Listing Standards
8. Ambry Genetics and RainDance Technologies Announce Partnership for Diagnostics and Genomics Services Utilizing the RDT 1000 for Sequence Enrichment and Targeted Resequencing Validation
9. Interleukin Genetics to Raise $5.3 Million in Registered Direct Offering
10. Viral Genetics CEO Issues State of the Company Update
11. Ambry Genetics Announces Launch of Their StemArray(TM) Product and Services for High Resolution Characterization of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 ... the  "Global Acute lymphocytic Leukemia Market and ... their offering.       (Logo: ... Lymphocytic Leukemia Market and Competitive Landscape Highlights ... Leukemia pipeline products, Acute Lymphocytic Leukemia epidemiology, ...
(Date:5/3/2016)... 2016 Research and Markets has ... Cell Therapy Market Outlook 2020" report to their ... , ,Recombinant technology has improved significantly in past years ... developed in coming years. Many cancer drugs have been ... therapies are also expected to be developed with its ...
(Date:5/3/2016)... Pa. , May 3, 2016 ACME ... Jack Whelan and Delaware County ... (naloxone HCI) Nasal Spray in all ACME ... U.S. Centers for Disease Control and Prevention (CDC), naloxone has saved ... when police officers in Delaware County were ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... 05, 2016 , ... Tim Dieter has announced the latest ... Dubuque, IA. The current campaign fundraises for Veteran’s Freedom Center on behalf of ... Freedom Center may now be made here: http://www.veteransfreedomcenter.com/donate/ . , Veteran’s Freedom ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... among Pittsburgh-area schoolchildren has found that more than 40 percent of participating fifth-grade ... MD , Director of Allergy and Asthma Clinical Research in the Division of ...
(Date:5/5/2016)... ... ... TIME for Kids and The ZAC Foundation – a national leader in drowning ... million children with important water safety messages before summer break begins. , ... in children one to 6 years of age. TIME for Kids and The ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... Drago presented a talk highlighting the organization’s successful Care Transitions program ... , The talk was titled “Minimizing Costs in the Post-Acute Environment Through Effective ...
(Date:5/5/2016)... ... ... The 2016 Nike Soccer Camp will be directed by the 2015 Big ... they bring their winning Vandals coaching philosophy to young athletes. Programs are offered for ... school players. Session dates are as follows: , Youth Day Camp – July 11th-14th, ...
Breaking Medicine News(10 mins):